Compounding Pharmacies and GLP-1s: What You Need to Know

When Wegovy and Mounjaro faced persistent shortages throughout 2023-2025, compounding pharmacies stepped in to fill the gap — literally. These pharmacies create custom formulations of semaglutide and tirzepatide at a fraction of brand-name prices. But the landscape is complex, and not all compounded GLP-1s are created equal.

What Is Compounding?

Pharmaceutical compounding is the practice of creating customized medications tailored to individual patient needs. Compounding pharmacies have existed for centuries and serve a legitimate role in healthcare — creating dosage forms, combinations, or strengths not available commercially.

Under FDA regulations, compounding pharmacies are permitted to compound copies of FDA-approved drugs when those drugs are on the FDA Drug Shortage List. This is what opened the door for compounded semaglutide and tirzepatide.

The Legal Landscape in 2026

The regulatory situation has evolved significantly:

• Semaglutide: Was removed from the FDA shortage list in early 2025 as Novo Nordisk increased production. This creates legal ambiguity for compounders continuing to produce it.
• Tirzepatide: Remains on the shortage list as of early 2026, meaning compounding is on firmer legal ground.
• State-by-state variation: Some states have additional regulations governing compounded injectables.

Multiple lawsuits between brand manufacturers and compounding pharmacies are currently working through the courts. The regulatory environment is fluid.

How to Evaluate a Compounding Pharmacy

If you're considering compounded GLP-1 medications, here's what to look for:

Non-Negotiable Requirements

• 503B registration: Outsourcing facilities registered under Section 503B of the FD&C Act are subject to FDA oversight, including current good manufacturing practices (cGMP) and regular inspections.
• Third-party potency testing: The pharmacy should test each batch for actual semaglutide/tirzepatide content and provide certificates of analysis.
• Sterility testing: Injectable medications must meet USP 797 sterility standards.
• Prescription requirement: Any pharmacy selling you GLP-1 medications without a valid prescription is operating illegally.

Red Flags

• No prescription required
• Prices that seem too good to be true (under $100/month should raise questions)
• Unable or unwilling to provide certificates of analysis
• Operating from overseas
• Marketing as "peptides" rather than as prescription medications
• Sold through social media without medical consultation

The cost savings from compounded GLP-1s can be substantial — often $200-400/month versus $1,000+ for brand name. But those savings are only meaningful if the product is safe, pure, and properly dosed.

Cost Comparison

Typical pricing ranges as of early 2026:

• Brand-name Wegovy: $1,300-1,400/month (without insurance)
• Brand-name Zepbound: $1,000-1,100/month (without insurance)
• Compounded semaglutide: $200-500/month (varies by pharmacy and dose)
• Compounded tirzepatide: $300-600/month (varies by pharmacy and dose)

The Brand Manufacturer Perspective

Novo Nordisk and Eli Lilly have both taken aggressive legal and regulatory action against compounding pharmacies. Their argument: compounded versions haven't undergone the rigorous clinical trials that established safety and efficacy for their branded products, and patients may be at risk from impure or improperly dosed formulations.

There's merit to this concern. FDA inspections have found contamination, sub-potent formulations, and sterility failures at some compounding facilities. However, well-regulated 503B facilities with proper quality controls can produce formulations that meet pharmaceutical standards.

Our Recommendation

If brand-name medications are financially accessible to you — through insurance, manufacturer savings programs, or out-of-pocket — they remain the safest choice. If compounded GLP-1s are your most viable path, insist on a 503B-registered facility and verify their testing protocols. Never purchase injectables from unregulated sources.